The Reallife Comparison of FOLFIRINOX vs Gemcitabine Platinum Combination as a First-Line Treatment in Patients with Pancreatic Carcinoma
Received Date : 23 Nov 2023
Accepted Date : 08 Feb 2024
Available Online : 26 Feb 2024
Doi: 10.37047/jos.2023-100383 - Article's Language: EN
Journal of Oncological Sciences. 2024;10(1):32-8.
This is an open access article under the CC BY-NC-ND license
Objective: The vast majority of pancreatic carcinoma patients have unresectable or metastatic disease at the time of diagnosis. Therefore, the 5-year survival rate is approximately 10%. FOLFIRINOX is used as a standard first-line therapy in patients with good performance status and as a single agent for patients with poor performance. Our study aimed to compare the combination of FOLFIRINOX and gemcitabine plus platinum-based therapy in the first-line treatment of unresectable metastatic pancreatic cancer. Material and Methods: Patients diagnosed with locally unresectable and metastatic pancreatic cancer at Gazi University Hospital between 01.2012 and 01.2020 were retrospectively screened. Results: The progression-free survival (PFS) and overall survival (OS) did not significantly differ between the FOLFIRINOX and gemcitabine plus platinum groups (p=0.22 and p=0.192, respectively). Moreover, there was no significant difference in the disease control rate (DCR) between the FOLFIRINOX and gemcitabine plus platinum groups (78.6% vs. 73.1%, respectively; p=0.64). The incidence of neutropenia fever and allgrade mucositis, diarrhea, and neuropathy was significantly greater in the FOLFIRINOX group (p=0.036, p=0.021, p=0.009, p=0.021, respectively). However, there were no significant differences in the incidence of Grade 3-4 side effects, interruption due to side effects, or treatment discontinuation (p=0.60, p=0.33, p=0.8, respectively). Conclusion: Although there was an improvement in OS of 4 months in favor of FOLFIRINOX, no statistically significant difference was found in the median OS, PFS, or DCR between patients treated with gemcitabine and patients treated with platinum agents.
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. [Crossref]  [PubMed] 
  2. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020. [Crossref]  [PubMed] 
  3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413. Corrected and republished in: J Clin Oncol. 2023;41(36):5482-5492. [Crossref]  [PubMed] 
  4. Louvet C, Labianca R, Hammel P, et al; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-3516. [Crossref]  [PubMed] 
  5. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29-34. [Crossref]  [PubMed] 
  6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946-3952. [Crossref]  [PubMed] 
  7. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23(6):1228-1236. [Crossref]  [PubMed] 
  8. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. [Crossref]  [PubMed] 
  9. Ducreux M, Cuhna AS, Caramella C, et al; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v56-68. Erratum in: Ann Oncol. 2017;28(suppl_4):iv167-iv168. [Crossref]  [PubMed] 
  10. Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer. 2013;49(3):593-603. [Crossref]  [PubMed] 
  11. Von Hoff DD, Ervin TJ, Arena FP, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. American Society of Clinical Oncology. 2013;31:4005. [Crossref] 
  12. Wang Y, Camateros P, Cheung WY. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and gemcitabine in advanced pancreatic cancers. J Gastrointest Cancer. 2019;50(1):62-68. [Crossref]  [PubMed] 
  13. Quan Q, Wang Y, Wang F, et al. Real world first-line treatments and outcomes of nab-paclitaxel plus gemcitabine, mFOLFIRINOX and GEMOX in unresectable pancreatic cancer from a Chinese Single Institution. Curr Oncol. 2020;28(1):209-219. [Crossref]  [PubMed]  [PMC] 
  14. Chan KKW, Guo H, Cheng S, et al. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis. Cancer Med. 2020;9(1):160-169. [Crossref]  [PubMed]  [PMC] 
  15. Kayahan N, Karaca M, Satış H, Yapar D, Özet A. Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. Turk J Med Sci. 2021;51(4):1727-1732. [Crossref]  [PubMed]  [PMC] 
  16. Caglevic C, Mahave M, Sanhueza C, Ubillos L. Current systemic treatment options for metastatic and unresectable pancreatic cancer. Pancreatic Cancer. IntechOpen; 2020. [Crossref]